Taikang and WuXi-backed CStone Pharmaceuticals has priced its shares near the middle of its proposed range to raise $285m in proceeds at a valuation of $1.5bn.

Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.

Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.

The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.

Nan Fung-backed biopharmaceutical company Stealth Bio has filed for an IPO that could bring in almost $87m if it floats at the top of the range.

The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.

VetMedUni biopharmaceutical spinout Marinomed Biotech has completed its IPO to attain a market cap of $109m.

A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.

Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018

Maoyan is floating in Hong Kong at the bottom of its range, in an offering that will provide exits to Enlight, Tencent and Meituan Dianping.